ATE411024T1 - Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen - Google Patents
Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzenInfo
- Publication number
- ATE411024T1 ATE411024T1 AT02758191T AT02758191T ATE411024T1 AT E411024 T1 ATE411024 T1 AT E411024T1 AT 02758191 T AT02758191 T AT 02758191T AT 02758191 T AT02758191 T AT 02758191T AT E411024 T1 ATE411024 T1 AT E411024T1
- Authority
- AT
- Austria
- Prior art keywords
- desoxypeganine
- intoxication
- diseases
- treatment
- nervous system
- Prior art date
Links
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000035987 intoxication Effects 0.000 title 1
- 231100000566 intoxication Toxicity 0.000 title 1
- 230000000506 psychotropic effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119863A DE10119863A1 (de) | 2001-04-24 | 2001-04-24 | Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411024T1 true ATE411024T1 (de) | 2008-10-15 |
Family
ID=7682410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02758191T ATE411024T1 (de) | 2001-04-24 | 2002-04-18 | Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040132751A1 (de) |
| EP (1) | EP1383503B1 (de) |
| JP (1) | JP2004526791A (de) |
| KR (1) | KR20030094365A (de) |
| CN (1) | CN1638774A (de) |
| AR (1) | AR033469A1 (de) |
| AT (1) | ATE411024T1 (de) |
| AU (1) | AU2002325209B2 (de) |
| BR (1) | BR0209125A (de) |
| CA (1) | CA2445132C (de) |
| CZ (1) | CZ20032788A3 (de) |
| DE (2) | DE10119863A1 (de) |
| DK (1) | DK1383503T3 (de) |
| EA (1) | EA200301134A1 (de) |
| ES (1) | ES2316595T3 (de) |
| HU (1) | HUP0303921A3 (de) |
| IL (1) | IL158383A0 (de) |
| MX (1) | MXPA03009766A (de) |
| MY (1) | MY135676A (de) |
| NO (1) | NO20034741L (de) |
| NZ (1) | NZ529005A (de) |
| PL (1) | PL366845A1 (de) |
| PT (1) | PT1383503E (de) |
| SI (1) | SI1383503T1 (de) |
| SK (1) | SK287214B6 (de) |
| WO (1) | WO2002087553A2 (de) |
| ZA (1) | ZA200308042B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10354893B4 (de) * | 2003-11-24 | 2011-03-10 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen |
| DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
| ES2360547B1 (es) * | 2009-11-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso. |
| US20220265582A1 (en) * | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| DE3315272C2 (de) * | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
| DE3843239C1 (de) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| US5602184A (en) * | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
| DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
| DE19906979B4 (de) * | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| DE19906978B4 (de) * | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
| DE19924951B4 (de) * | 1999-05-31 | 2004-02-05 | Lts Lohmann Therapie-Systeme Ag | Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer |
| EP1231877A4 (de) * | 1999-11-04 | 2009-03-18 | Xel Herbaceuticals | Transdermale verabreichung von huperzin |
-
2001
- 2001-04-24 DE DE10119863A patent/DE10119863A1/de not_active Withdrawn
-
2002
- 2002-04-18 MX MXPA03009766A patent/MXPA03009766A/es active IP Right Grant
- 2002-04-18 IL IL15838302A patent/IL158383A0/xx not_active IP Right Cessation
- 2002-04-18 SK SK1316-2003A patent/SK287214B6/sk not_active IP Right Cessation
- 2002-04-18 SI SI200230779T patent/SI1383503T1/sl unknown
- 2002-04-18 AU AU2002325209A patent/AU2002325209B2/en not_active Ceased
- 2002-04-18 ES ES02758191T patent/ES2316595T3/es not_active Expired - Lifetime
- 2002-04-18 HU HU0303921A patent/HUP0303921A3/hu unknown
- 2002-04-18 DK DK02758191T patent/DK1383503T3/da active
- 2002-04-18 CN CNA028088891A patent/CN1638774A/zh active Pending
- 2002-04-18 US US10/475,788 patent/US20040132751A1/en not_active Abandoned
- 2002-04-18 WO PCT/EP2002/004278 patent/WO2002087553A2/de not_active Ceased
- 2002-04-18 NZ NZ529005A patent/NZ529005A/en unknown
- 2002-04-18 AT AT02758191T patent/ATE411024T1/de not_active IP Right Cessation
- 2002-04-18 EA EA200301134A patent/EA200301134A1/ru unknown
- 2002-04-18 CZ CZ20032788A patent/CZ20032788A3/cs unknown
- 2002-04-18 BR BR0209125-9A patent/BR0209125A/pt not_active IP Right Cessation
- 2002-04-18 JP JP2002584899A patent/JP2004526791A/ja active Pending
- 2002-04-18 KR KR10-2003-7013972A patent/KR20030094365A/ko not_active Ceased
- 2002-04-18 CA CA002445132A patent/CA2445132C/en not_active Expired - Fee Related
- 2002-04-18 PL PL02366845A patent/PL366845A1/xx not_active IP Right Cessation
- 2002-04-18 DE DE50212901T patent/DE50212901D1/de not_active Expired - Lifetime
- 2002-04-18 PT PT02758191T patent/PT1383503E/pt unknown
- 2002-04-18 EP EP02758191A patent/EP1383503B1/de not_active Expired - Lifetime
- 2002-04-22 MY MYPI20021470A patent/MY135676A/en unknown
- 2002-04-24 AR ARP020101483A patent/AR033469A1/es unknown
-
2003
- 2003-10-16 ZA ZA200308042A patent/ZA200308042B/en unknown
- 2003-10-23 NO NO20034741A patent/NO20034741L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE316077T1 (de) | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten | |
| ATE518841T1 (de) | Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas | |
| DE602004022061D1 (de) | Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| ATE390925T1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| DE60320007D1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| ATE524479T1 (de) | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren | |
| DE60328517D1 (de) | Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung | |
| ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| DE60304695D1 (de) | 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN | |
| ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
| DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
| EP1117395A4 (de) | Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden | |
| ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| ATE378052T1 (de) | Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE60130691D1 (de) | Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems | |
| DE50212901D1 (de) | Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
| DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
| ATE458481T1 (de) | Kombination von phenylcarbonsäureamiden mit blockern des ikr-kanals und deren verwendung zur behandlung von vorhofarrhythmien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |